Christopher J. Sweeney, MBBS
The FDA recently expanded the approval of abiraterone acetate (Zytiga) to include the treatment of patients with metastatic high-risk castration-sensitive prostate cancer, based on findings from the phase III LATITUDE trial.
, Christopher Sweeney, MBBS, a medical oncologist at Dana-Farber Cancer Institute, discussed the role of abiraterone for patients with hormone-sensitive prostate cancer, and what physicians should consider when choosing between abiraterone and docetaxel.
OncLive: How do you determine whether to administer docetaxel or abiraterone to patients with prostate cancer?
Determining between abiraterone and docetaxel is a challenge, as both drugs work well. Abiraterone is an easier drug for most patients to tolerate because it is a hormonal therapy. Docetaxel also has activity, but it has a higher treatment burden.
... to read the full story